Journal Article Summary
The article investigates the gastrointestinal (GI) side effects associated with semaglutide 2.4 mg, a medication used for weight management in adults with overweight or obesity. Understanding the tolerability of this medication is important because GI adverse events, such as nausea and diarrhea, are common side effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs). These side effects can impact patient adherence to treatment and overall weight loss outcomes, making it crucial to evaluate their frequency and severity in relation to the drug's effectiveness.
The study analyzed data from three clinical trials involving 2,117 participants taking semaglutide and 1,262 receiving a placebo over 68 weeks. The findings revealed that GI adverse events were more frequent in those taking semaglutide, with nausea being the most common side effect reported by 43.9% of participants. However, most of these events were mild to moderate, transient, and did not lead to significant treatment discontinuation, with only 4.3% of participants stopping the medication due to GI issues. Importantly, the weight loss achieved with semaglutide was largely independent of these GI adverse events, indicating that the medication's effectiveness was not significantly affected by the presence of side effects.
Despite the reassuring results, the study has limitations, including its post hoc nature and the potential for bias in self-reported adverse events. Patients should be aware that while GI side effects are common, they are typically not serious and tend to resolve over time. It is advisable for individuals considering semaglutide to discuss any concerns about side effects and weight loss goals with their healthcare provider, who can provide tailored advice and support for managing any adverse effects during treatment.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Wharton Sean, Calanna Salvatore, Davies Melanie, Dicker Dror, Goldman Bryan, Lingvay Ildiko, Mosenzon Ofri, Rubino Domenica M., et al.. Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes, Obesity & Metabolism 2021. DOI: 10.1111/dom.14551. PMID: 34514682. PMCID: PMC9293236.
Featured Pill Pals Product
Semaglutide with B-12 --- 10 mg / 2 mg / 4 ml --- 4 ml vial --- Weight Loss Glucagon-Like Peptide-1 (GLP-1)
Semaglutide with B-12 --- 10 mg / 2 mg / 4 ml --- 4 ml vial --- Weight Loss Glucagon-Like Peptide-1 (GLP-1) is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. Prescription required.
